Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By afschroeder • March 25, 2026

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Rickard K, O'Donovan K, Sciurba F. Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials). Adv Ther. 2026 Mar 24. doi: 10.1007/s12325-026-03514-6. Epub ahead of print. PMID: 41874851.

Tags: COPD, Dual PDE3, ensifentrine, nebulized therapy, PDE4 Inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

Feasibility, acceptability, and usability of a novel self-monitoring program utilizing a consumer-grade wearable device paired with sleep-related patient-reported outcomes for veterans with obstructive sleep apnea

Mak S, Ghadimi S, Der-McLeod E, Naeem S, Moore V, Gil L, Chohan M, Zeidler M, Ash G, Fung C. Feasibility, acceptability, and usability of[...]

Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic diseases: real-world data from the ILD-PRO Registry

Bracken SJ, Weber JM, Neely ML, Swaminathan AC, Palmer SM, Wilfong EM, Chauffe AD, Volkmann ER. Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic[...]

Inflammatory and immune biomarkers over midlife and future cognition in women: the SWAN HDL Ancillary Study

Qi M, Derby CA, Rader D, Janssen I, Barinas-Mitchell E, Brooks MM, Chang CH, Karlamangla AS, McConnell D, Crawford S, El Khoudary SR. Inflammatory and[...]